Label Image (Lbl500907771)
Levetiracetam Tablet, Film Coated
Product Images NDC 50090-7771
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 50090-7771). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
This is a description of Figure 1 displaying the Responder Rate with a 250% Reduction from Baseline in Study 1. The graph shows varying percentages of responders, with one point being statistically significant compared to placebo.*
Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
This text provides data on responder rates in Study 2, specifically during Period A. It includes percentages of patients responding to treatment with placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The study indicates that the responder rate for Levetiracetam 2000 mg/day is statistically significantly different from that of placebo.*
Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This is a bar graph showing the Responder Rate (>50% Reduction from Baseline) in Study 3 comparing Placebo (N=104) and Levetiracetam 3000 mg/day (N=180) groups. Levetiracetam at the mentioned dosage showed a statistically significant improvement in responder rates compared to the placebo group.*
Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
This text shows the responder rates (50% reduction from baseline) in Study 4 for the placebo group (N=97) and the Levetiracetam group (N=101). The Levetiracetam group had a responder rate of 44.6%, which was statistically significant compared to the placebo group's responder rate of 19.6%.*
Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
This is a figure providing data on the Responder Rate for All Patients Ages 1 Month to less than 4 Years, showing more than a 50% reduction from the baseline in Study 5. The comparison is between Placebo and Lovetracatam, indicating a statistically significant difference in their effectiveness.*
Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
This image shows the Responder Rate (250% Reduction from Baseline) in primary generalized tonic-clonic (PGTC) seizure frequency per week in Study 7. It compares the results for patients receiving a placebo (N=84) and those treated with Levetiracetam (N=79). The graph indicates a statistically significant improvement in the responder rate for patients on Levetiracetam compared to those on placebo.*
Chemical Structure (Levetiracetam Str)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
